Stachydrine hydrochloride inhibits osteoclastogenesis by regulating the NF-κB and p38 signaling pathways to alleviate postmenopausal osteoporosis
| Autor: | Xuantao Hu, Zhengxiao Ouyang, Guangyao Jiang, Minghui Chen, Tao Li, Jianliang Deng, Daishui Yang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Chemistry p38 mitogen-activated protein kinases Osteoporosis Biophysics NF-κB Cell Biology medicine.disease Biochemistry Bone resorption Pathogenesis 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Skeletal disorder Osteoclast 030220 oncology & carcinogenesis medicine Cancer research Signal transduction Molecular Biology |
| Zdroj: | Biochemical and Biophysical Research Communications. 542:1-8 |
| ISSN: | 0006-291X |
| Popis: | Osteoporosis is a common skeletal disorder characterized by low bone mass, defective bone microstructure, and increased risk of fracture. It’s well known that excessive activation of osteoclasts plays a vital role in the pathogenesis of osteoporosis. Thus, inhibition of osteoclast formation and function might be a proving strategy for osteoporosis. In our study, for the first time we explored the effect of Stachydrine Hydrochloride in the treatment of osteoporosis. We demonstrated that SH markedly inhibited osteoclastogenesis and osteoclast function in vitro and effectively decrease bone resorption in vivo. These finding were further supported by changes in the NF-κB and p38 signaling pathways, which are classical downstream pathways of RANKL-mediated osteoclastogensis. Collectively, these data suggest the possible future use of SH to protect against bone loss in the treatment of osteoporosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect